Signi fi cant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and pd-1/pd-l1 immunotherapy

HIGHLIGHTS

• who: PD-L et al. from the Huazhong University of Science and Technology, China have published the paper: Signi fi cant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy, in the Journal: (JOURNAL)
• what: The authors used a nontargeted metabolomics approach based on liquid chromatography-mass spectrometry to analyze the metabolic response of NSCLC patients to EGFR-TKIs or PD-1/PD-L1 inhibitors in an attempt to provide new clues to identifying the antitumor mechanism of these two treatments from . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.